Bisphosphonates, raloxifene and teriparatide for treating osteoporosis

24th August 2018 by Louise Hudman

Bisphosphonates, raloxifene and teriparatide for treating osteoporosis

This summary is based on 3 recent NICE guidelines:

Previous guidance was rather complicated in that different bisphosphonates could be used at different levels of risk. This has all been simplified as the cost of the drugs has reduced. Advice on using raloxifene and teriparatide hasn’t changed. Strontium and etidronate are no longer marketed in the UK.

There is quite a nice decision aid that can be used with patients on what the risk reduction is with different treatments.

Who is eligible for bisphosphonate treatment?

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I have decided to retire from medicine, and so from the NASGP too. You have my heartfelt thanks for being around, especially for all the useful articles in your journal, and I wish you well for the future. "

Dr Stephen Pope

See the full list of features within our NASGP membership plans

Membership